- In January 5, 2024, Medtronic received the CE Mark for its next-generation Micra AV2 and Micra VR2 leadless pacemakers. These devices offer approximately 40% more battery life than previous models, with projected lifespans of nearly 16 and 17 years, respectively. Additionally, the Micra AV2 features advanced algorithms to optimize atrioventricular (AV) synchrony and supports higher tracking capabilities for faster heart rates
- On August 2022, Cornell University scientists tested their newly developed pacemaker on mini-donkey suffering from severe cardiac disease to detect its efficacy in managing fatal heart conditions. Veterinarians conducted an EEG/echocardiography & installed an ECG on the donkey to record its heart beating. It showed highly positive results, and within a month or two, the donkey's condition gradually improved. Cornell University announced that its new pacemaker would receive FDA approval within the next month for its launching in the market
- In June 2021, India Medtronic Private Limited launched Micra AV, a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to atrioventricular (AV) block patients via a minimally invasive approach. The device is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart
- In January 2021, Boston Scientific Corporation announced its plan to acquire the remote cardiac monitoring developer, Preventice Solutions
- In May 2020, BIOTRONIK launched a home monitoring system for providing safe and cost-effective management for patients with pacemakers
- On January 2020, Medtronic announced FDA approval for its product Micra AV, the world’s smallest 2nd generation wireless pacemaker directly implanted into the heart
